Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Eli Lilly and Company
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Treatment with metformin for at least 2 months
Has HbA1c 7.0% to 11.0%, inclusive, at screening
Body mass index (BMI)25 kg/m\^2 to 45 kg/m\^2, inclusive
List of medications that are not allowed or the patient has been on stable treatment for at least 2 months:
* Hormone replacement therapy (female subjects)
* Oral contraceptives (female subjects)
* Antihypertensive agents
* Lipid-lowering agents
* Thyroid replacement therapy
You may not be if
Has been treated with exenatide (BYETTA®) or any DPP-4 inhibitor prior to screening
Received any study medication or participated in any type of clinical trial within 30 days prior to screening
Has donated blood within 60 days of screening visit or is planning to donate blood during the study
Treated with any of the following medications:
* Sulfonylurea or Thiazolidinedione within 3 months of screening;
* Alpha-glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®)within 30 days of screening;
* Insulin within 2 weeks prior to screening or insulin for longer than 1 week within 6 months of screening;
* Drugs that directly affect gastrointestinal motility, including but not limited to, anticholinergics, macrolide antibiotics, dopamine antagonists, opioids, and Reglan®(metoclopramide);
* Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption;
